The European Commission

R&D

We have seen a boom in biotech initial public offerings over the last two years, but many of Europe’s offerings have migrated to the United States.

News

The FDA stops short of approving leucovorin for autism, but will its clearance for ultra-rare condition CFD-FOLR1 lead to more off-label prescribing?

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.